Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Price Target at $126.00

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $126.00.

A number of research analysts have weighed in on the stock. Leerink Partners lifted their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research report on Thursday, July 11th. Truist Financial decreased their price target on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective on the stock. JMP Securities decreased their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research report on Thursday, August 1st. Finally, B. Riley raised their target price on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the transaction, the chief accounting officer now directly owns 62,557 shares of the company's stock, valued at approximately $4,990,171.89. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction dated Thursday, June 13th. The shares were sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the sale, the chief accounting officer now owns 62,557 shares of the company's stock, valued at approximately $4,990,171.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the company's stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. The disclosure for this sale can be found here. Insiders sold a total of 41,193 shares of company stock worth $3,949,202 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC boosted its holdings in Lantheus by 0.4% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock worth $1,834,000 after purchasing an additional 100 shares during the period. Moody National Bank Trust Division boosted its holdings in shares of Lantheus by 1.1% in the 2nd quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock valued at $1,203,000 after buying an additional 162 shares during the period. Shaker Investments LLC OH boosted its holdings in shares of Lantheus by 0.7% in the 1st quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider's stock valued at $1,740,000 after buying an additional 182 shares during the period. NBC Securities Inc. raised its stake in Lantheus by 28.4% during the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider's stock worth $53,000 after acquiring an additional 191 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 208 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Trading Up 2.9 %

Shares of NASDAQ LNTH traded up $2.87 during trading on Wednesday, hitting $101.95. 645,647 shares of the company traded hands, compared to its average volume of 1,029,078. The firm has a market capitalization of $7.08 billion, a P/E ratio of 15.56 and a beta of 0.50. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average price of $103.44 and a 200-day moving average price of $82.08. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Lantheus's revenue was up 22.5% on a year-over-year basis. During the same period last year, the firm posted $1.40 EPS. On average, equities analysts predict that Lantheus will post 5.99 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.